Using human recombinant MIF from transfected COS-1 cells, we have shown that this lymphokine upregulates several macrophage molecules associated with activation (HLA-DR, IL-1beta, TNFalpha, and nitric oxide), activates macrophage to kill protozoa (intracellularly) and tumor cells (extracellularly), and enhances the clumping and adhesion of macrophages to each other. For controls, we used supernatants containing non-active """"""""stopMIF"""""""" from COS-1 cells transfected with a mutated MIF-cDNA containing a stop codon. Human rMIF acts on murine cells in vitro, and when given with an antigen to mice in vivo, it elicits an antigen-dependent lymph node T cell proliferative response in as great as that elicited by complete Freund's adjuvant. Finally, preliminary studies show that the in vivo adjuvant effect of complete Freund's adjuvant is totally abrogated by antibodies to rMIF.
The specific aims of this proposal are: 1. To produce and purify biologically active recombinant MIF in reasonable quantity. 2. To determine the mechanism of the adjuvant action of rMIF. This will include studies on the effect of rMIF on antigen processing, on integrin activity and expression, and on its interaction with other cytokines. 3. To ascertain the mechanism for the recent finding that, when given to mice, antibodies to rMIF abrogate the adjuvant action of complete Freund's adjuvant. 4. To use purified labelled rMIF to obtain the rMIF receptor, by direct receptor expression cloning or by immunochemical means.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI022532-09
Application #
3133726
Study Section
Immunobiology Study Section (IMB)
Project Start
1985-01-01
Project End
1997-12-31
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
9
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
Schools of Public Health
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Satoskar, A R; Bozza, M; Rodriguez Sosa, M et al. (2001) Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun 69:906-11
Satoskar, A R; Rodig, S; Telford 3rd, S R et al. (2000) IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30:834-9
Bozza, M; Satoskar, A R; Lin, G et al. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341-6
Ochi, H; Hirani, W M; Yuan, Q et al. (1999) T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 190:267-80
Satoskar, A R; Stamm, L M; Zhang, X et al. (1999) Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection. J Immunol 162:6747-54
Stamm, L M; Satoskar, A A; Ghosh, S K et al. (1999) STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol 29:2524-9
Soares, M B; Titus, R G; Shoemaker, C B et al. (1998) The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. J Immunol 160:1811-6
Bozza, M; Soares, M B; Bozza, P T et al. (1998) The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur J Immunol 28:3120-7
Stamm, L M; Raisanen-Sokolowski, A; Okano, M et al. (1998) Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J Immunol 161:6180-8
Soares, M B; David, J R; Titus, R G (1997) An in vitro model for infection with Leishmania major that mimics the immune response in mice. Infect Immun 65:2837-45

Showing the most recent 10 out of 45 publications